Here’s whether AstraZeneca PLC (AZN) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Neutral.
🔵
Neutral
Positives: trading above the 200-day MA (long-term uptrend intact); RSI 55 — healthy momentum range; strong 1-year return of +167.4%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-1.34% over 10 days); 3-month momentum negative (-9.5%). Currently 12.1% off its 52-week high. Score: +1/7.
AZN is holding above its long-term 200-day MA ($127.95) but has slipped below the 50-day MA ($191.23), pointing to short-term weakness in an otherwise intact trend. An RSI of 55.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +167.4% compares to +27.9% for SPY (beat the market by 139.5%).
$10,000 invested 1 year ago→ $26,738 today
vs. S&P 500 (SPY) — same period beat market by 139.5%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($127.95)
✗Above 50-day MA ($191.23)
✓RSI(14) neutral zone (30–70) — currently 55.5
✓Positive return (+167.4%)
!Within 10% of period high (−12.1%)
Period Range $187.03
$68.62$212.71
RSI (14) 55.5
0 · OversoldOverbought · 100
Key Metrics
Price$187.03
Period Return+167.4%
Period High$212.71
Period Low$68.62
Drawdown−12.1%
MA-50$191.23
MA-200$127.95
RSI (14)55.5
Avg Volume (30d)2.0M
vs. SPYbeat by 139.5%
Return Rank#137 of 1236
Trend Signals
Price is above the 200-day moving average ($127.95)
Price is below the 50-day moving average ($191.23)